Nova Measuring Instruments Ltd. — FY2014 Form 20-F
Reporting period: Fiscal year ended December 31, 2014; filed February 25, 2015. This is an annual report, not a standalone fourth-quarter filing. The supplied filing text does not provide a clear set of Q4-only financial results. Figures below are consolidated U.S. GAAP amounts in U.S. dollars.
Business context
Nova designs and sells optical metrology and process-control systems, software and related services for semiconductor manufacturing. Products include integrated tools installed in process equipment and stand-alone metrology systems. Demand is linked to semiconductor manufacturers’ capital spending and the industry’s cyclical investment patterns.
Financial performance and position
| Metric | FY2014 | FY2013 |
|---|---|---|
| Revenue | $120.6 million | $111.5 million |
| Gross profit / gross margin | $63.6 million / 52.7% | $59.1 million / 53.0% |
| Operating profit / operating margin | $16.9 million / 14.0% | $12.3 million / 11.1% |
| Net income | $18.7 million | $10.5 million |
| Diluted earnings per share | $0.67 | $0.38 |
| Cash flow from operating activities | $33.5 million | $11.0 million |
| Cash, cash equivalents and bank deposits | $121.7 million | $97.8 million |
| Working capital | $130.5 million | $118.6 million |
| Total assets | $173.3 million | $162.3 million |
| Total liabilities | $29.7 million | $33.6 million |
| Shareholders’ equity | $143.6 million | $128.7 million |
Cash, cash equivalents and bank deposits include $13.6 million of cash and equivalents, $107.3 million of short-term deposits and $0.75 million of long-term deposits in 2014. The company reported no significant long-term debt and no readily available long-term credit line. Operating cash flow funded $5.2 million of capital expenditures; investing cash flow also reflected increased deposits. The company ended 2014 with $13.6 million in cash and equivalents, versus $17.5 million a year earlier.
Product revenue was $92.2 million (76.4% of total revenue), up 3%; service revenue was $28.4 million (23.6%), up 29%. Management reported product gross margin of 57% and service gross margin of 39%. Inventory was $16.1 million, down from $18.1 million, and receivables were $15.6 million, down from $27.9 million. Net research and development expense was $29.5 million, or 24.5% of revenue. The filing reports 404 employees at year-end.
Changes versus prior year and notable items
- Revenue rose 8% from 2013, following 16% growth in 2013. Management attributed 2014 product growth partly to greater adoption of software products and service growth to a larger installed base, more service contracts and upgrades.
- Operating profit increased 37% and net income increased 77%. Operating expenses were broadly flat at $46.7 million; higher revenue and lower G&A expense improved operating margin.
- Gross margin edged down from 53.0% to 52.7%. Product margin fell from 58% to 57%, reflecting new process-step penetration and higher third-party royalties; service margin improved from 34% to 39% as service revenue grew.
- FY2014 income taxes were a $1.2 million benefit, versus $2.5 million of expense in 2013, mainly due to Israeli tax incentives and recognition of deferred tax assets. Management recorded $1.8 million of net deferred tax assets at year-end.
- Operating cash flow rose to $33.5 million, supported in part by a $12.4 million reduction in receivables and a $2.2 million reduction in inventory. Repurchases totaled $6.7 million for 639,831 shares through year-end; through February 3, 2015, cumulative repurchases under the $12 million program were $6.7 million.
- Inventory write-offs were $1.6 million in 2014, compared with $1.8 million in 2013. Derivative-related other comprehensive income was a $1.7 million loss in 2014.
Outlook, risks and contingencies
Management planned to increase aggregate operating expenses in 2015 and expected approximately $8.1 million of capital expenditures, chiefly for information systems, R&D equipment and facility expansion. Its priorities included growth in foundry and memory customers, ramps at 16/14nm nodes, development for 10nm and 7nm nodes, advanced 3D structures, and increased software revenue. Industry estimates cited in the filing forecast 2015 WFE spending growth of 6.7% and semiconductor revenue growth of 5.4%; these are third-party forecasts, not company guidance.
- Concentration and cyclicality: The five largest customers represented 74% of revenue in 2014; one customer accounted for 36% and another 21%. Taiwan represented 45% of revenue by installation location. Semiconductor-equipment spending, orders and quarterly results can fluctuate materially.
- Product and execution risks: A substantial share of sales depends on two product lines. Competition, rapid technology change, product quality or shipment delays, and reliance on process-equipment partners could impair results. Backlog may be cancelled, delayed or rescheduled.
- Operational and geopolitical exposure: Manufacturing is concentrated at one facility in Israel; regional hostilities, reserve military service, supplier disruption or other facility interruptions could affect production. International sales expose the company to economic, political and trade risks.
- Currency and cash concentration: Revenue is largely in U.S. dollars while significant costs are in NIS and other currencies. The company used foreign-exchange forwards and options; derivative notional value was approximately $59.5 million at year-end. More than 95% of cash reserves were held with Israeli banks, with approximately 44% at one institution.
- Government grants and other obligations: OCS-funded technology carries royalty and Israeli manufacturing and technology-transfer restrictions. The filing states contingent OCS grant obligations of approximately $22.6 million in the financial-statement note (and approximately $22.9 million elsewhere in the report); royalty expense was $1.0 million in 2014. Contractual obligations totaled $25.0 million, including $16.8 million of purchase obligations.
- Other risks: Intellectual-property claims, potentially uncapped contractual liability, tax uncertainty and possible PFIC classification for U.S. investors are disclosed. The company believed it was not a PFIC in 2014 but acknowledged uncertainty. No significant legal proceedings were reported.
Management stated that available cash was sufficient for planned activities for at least 12 months. The independent auditor issued unqualified opinions on the financial statements and on internal control over financial reporting as of December 31, 2014. No cash dividends were expected for at least several years.
Investor verification priorities
- Review the full audited statements and notes, especially cash-flow drivers, the composition and maturity of deposits, and how the reported cash-reserve figures reconcile.
- Verify customer concentration and revenue exposure to leading customers, Taiwan, and the two principal product lines; assess the implications of the Q4 sales-volume decline noted by management.
- Track 2015 spending, capital expenditures, new-product adoption, customer ramps and whether growth supports the planned increase in operating expenses.
- Reconcile the OCS contingent-liability figures and assess grant-related royalties, manufacturing restrictions and possible tax-benefit clawbacks.
- Assess bank-deposit concentration, currency-hedge effectiveness, the share-repurchase program and the potential dilution from outstanding options and restricted stock units.